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The Sunday Times Business Times published a supplement
on the pharmaceutical industry on 30 November 2003. This
has been an extremely dynamic environment and one that
will be affected by impending legislative change. The
objective of the survey was to provide some insight into the
current status of the industry – special attention was paid
to costs of medication, generic medication and
antiretroviral therapy. This article aims to provide a
summary of the publication and provide background
information where necessary.
Generic medicines are copies of branded (original)
medicines that are produced and sold at lower costs once
the originator’s patent protection period has lapsed.
Multinational companies invest significantly on the
research and development of new medicines. It is quoted
that, of a batch of 10 000 molecules investigated, only one
will make it to market, with a research and development
cost of hundreds of millions of dollars. In order to allow the
originating multinational pharmaceutical company to
recoup research and development costs, a 20-year patent
protection period is allowed. This period is often
significantly reduced as extensive safety testing needs to
take place before marketing of the new medication.
Once the patent has lapsed, producers of generic drugs are
able to manufacture generic copies of the medication.
These are invariably sold for a much lower price, bringing
about a saving for the consumer.
While much is said about the spiralling costs of medicines,
there has been a reduction in the prices of many medicines.
This has been brought about largely by the emergence of
generics and its effect on costing models. It is
acknowledged, however, that multinationals need to be
afforded some protection, as they play a major role in the
development of innovative new medications.
It is widely accepted that generic medications have a role
to play in providing high-quality, affordable health care.
Uptake of generic medication in South Africa still lags
behind that of other developed markets.
The comparatively low use of generic medicines in South
Africa has been attributed to mistrust on the part of
doctors and patients, who have historically held the view
that these medications are inferior because they are
cheaper. The generic market is growing rapidly in South
Africa, however, and it is anticipated that impending
legislation will expedite this process.
Amendments to the Medicines and Related Substances
Control Amendments Act (Act 90), intended for
implementation in May 2004, have been made to provide a
transparent costing model for medication, with the
objective of reducing medication costs.
The new legislation will set a single factory exit price for
each medication — this price list will be in the public
domain. Medicine dispensers (doctors and pharmacists) will
not be able to add a mark-up, but will instead charge a
regulated professional fee for their service. In this way the
consumer knows how much is being paid for the medicine
and what is being paid for the dispensing and distribution.
Currently dispensers of medicine receive a percentage
mark-up on medications — this clearly provides an
incentive to use more expensive medicines in order to
maximise profit margins. The price list,  as well as the
professional fees, will be determined by a pricing
committee appointed by the Minister of Health.
There has been mixed reaction to the impending legislation,
with some applauding the initiative as a bold step by the
Government, while others criticise the practicality of the
legislation.
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Supporters believe that the legislation will provide a
transparent pricing system that will not tolerate perverse
incentives, back-handers and excessive profit margins.
Detractors feel that implementation is likely to encounter a
few practical difficulties and ignores the high likelihood of
cost shifting. If an individual/pharmacy is currently earning
a specific quantum of revenue, and this is cut, it is not
impossible that profits will be recouped by increasing costs
in non-regulated areas. In this case, the consumer pays the
same (or more) and does not necessarily receive that
appropriate care. If this has an adverse effect on the health
of the patient, total health care expenditure increases.
It appears that there is still a lack of
clarity about final implementation
details, and the industry will need to
wait for further information and
assess the situation at the time of
implementation.
The issue of the provision of
affordable antiretroviral therapy
(ART) received special focus in the
survey, with an emphasis on generic
medications in South Africa.
There has been good news on the
issue of generic antiretroviral
medication, with widespread
availability of these drugs being
predicted in the near future. This
has been brought about through
agreements between multinational
pharmaceutical companies and
generic medication manufacturers. On the one hand the
need for affordable ART is too great to apply the patent
protection period of 20 years, and on the other, the
multinationals need to reap some benefit in order to fund
further research and development.
A rational solution to this problem has been arrived at
through the granting of voluntary licensing agreements by
multinationals to generic manufacturers whereby the
generic manufacturer is able to utilise the applicable
intellectual property for a small royalty fee, or by limitation
of the licence to a stipulated geographical region.
Additional good news reported on was the announcement
by the Clinton Presidential Foundation of an initiative
aimed at reducing the cost of antiretroviral drugs in
developing countries. The initiative involves a venture with
two Indian pharmaceutical companies and a South African
generic medicine manufacturer (Aspen Pharmacare). These
companies will be manufacturing generic antiretroviral
medication — funding from the Foundation will allow a
further reduction in price. A target annual cost quoted is
US$140 for HAART.
BMW South Africa have had considerable success with
their workplace-based HIV/AIDS programme. An article on
this outlined the comprehensive approach that this
organisation has taken, including prevention, voluntary
counselling and testing (VCT) and
treatment of HIV- infected
employees.
Ian Robertson, Managing Director
of BMW SA, emphasised the need
to see AIDS as a business issue that
needs to be addressed with the
same vitality as would be the case
with other risks facing the business.
It is clearly this attitude which has
contributed to the success that has
been achieved in the programme.
A notable success has been the
uptake rate in the company’s VCT
initiative, with 87% of staff having
participated over a period of 20
months. VCT is a crucial element of
a comprehensive programme,
providing the link between
prevention and treatment. Once an
individual is aware of his/her HIV
status he/she is empowered to act
appropriately — if HIV-negative, to take action to remain
negative, and if positive, to access management of the
condition.
The point is well made in the article that implementation of
an effective HIV/AIDS programme in the workplace is not
necessarily a costly initiative. Much can be done to manage
the epidemic at fairly low cost. In order to assist companies
in this endeavour, the South African Business Coalition of
HIV/AIDS (SABCOHA) will be launching an HIV/AIDS
Workplace Programme toolkit in the first quarter of 2004.
The Sunday Times Business Times survey of the
pharmaceutical industry gave valuable insights into a small
but important range of issues affecting the health care
industry. 
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